Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04996199
Other study ID # suman008
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date September 18, 2021
Est. completion date January 31, 2022

Study information

Verified date August 2021
Source Postgraduate Institute of Dental Sciences Rohtak
Contact Sanjay Tewari, MDS
Phone 01262283876
Email principalpgidsrohtak@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Trigeminal neuralgia is a neuropathic facial pain condition, characterized by unilateral paroxysmal pain which can be described as stabbing or electric shock like, in the distribution of one or more divisions of trigeminal nerve which is triggered by innocuous stimuli. The attack is provoked by touching or stimulating these trigger zones. There are various pharmacological drugs present for the treatment of trigeminal neuralgia. Carbamazepine and oxcarbazepine are the first-choice drugs for the treatment of TN. Other drugs include lamotrigine , baclofen , gabapentin, antidepressants , eslicarbazepine , sumatriptan & vixitrigine. The carbamazepine is first choice of drug which has serious side effects including dizziness, memory loss, sleppiness, aplastic anaemia. Oxcarbazepine has similar mechanism of action and found to have lesser adverse events when used in various neuralgias in the place of carbamazepine. But there is still lack of evidence to prove that oxcarbazepine can be used as monotherapy in TN patients.


Description:

Trigeminal neuralgia is a neuropathic facial pain condition which is characterised by unilateral paroxysmal pain which is excruciating, short lasting in the distribution territory of trigeminal nerve.(1) Trigeminal neuralgia is oro-facial pain restricted to one or more divisions of the trigeminal nerve. With the exception of Trigeminal Neuralgia caused by Multiple sclerosis, the pain affects one side of the face. It is abrupt in onset and typically lasts only a few seconds (2 min at maximum).Patients may report their pain as arising spontaneously, but these pain paroxysms can always be triggered by innocuous mechanical stimuli or movements. Patients usually do not experience pain between paroxysms. If they do report additional continuous pain, in the same distribution and in the same periods as the paroxysmal pain, they are considered to have Trigeminal Neuralgia with continuous pain. (IASP)(1) Trigeminal neuralgia is mainly classified into three diagnostic categories i.e. Classical, Secondary and Idiopathic. This classification is mainly based on the etiology & pain characteristics. The etiology of Trigeminal Neuralgia is not well understood, but various theories such as Compression of sensory root of trigeminal nerve by arteries & bony exostoses.(4) ,focal demyelination of trigeminal afferents near the entry of the trigeminal root into pons(2)and alteration in the central neural function followed by injury to peripheral nerves (4) are widely accepted. Trigeminal Neuralgia has a profound effect on quality of life of the patient & expenditure on health (4). Due to the severe intensity of pain, patients avoid touching face, washing face, thus making patient's life disturbing & miserable. Even after so many years of research, it is still a challenge to treat patients suffering from Trigeminal Neuralgia. Treatment can be sub- divided into pharmacological & invasive therapies . The pharmacological therapy include drugs such as carbamazepine ( 200-1200mg) , oxcarbazepine (300-1800mg) , lamotrigine, Gabapentin , baclofen, eslicarbazepine, sumatriptan, vixotrigine. The pre- surgical procedures like botulinium toxin A & intranasal non-inhaled CO2 have also been sporadically used (1). A review study discussing the pharmacological options to treat trigeminal neuralgia concluded that carbamazepine & oxcarbazepine are the first choice of drugs(1). Oxcarbazepine showed equal efficacy in reducing pain attacks with better tolerability & less side effects (1) . A recently conducted study found that carbamazepine is associated with serious side effects including CNS disturbances, somnolence, unbalance, thrombocytopenia, increase level of transaminases while OXC showed similar efficacy with less side effects. CNS disturbances encountered in patients on CBZ were triple to those on OXC & withdrawal from the treatment was also more in patients on CBZ(27%) than on OXC (18%)(12). OXC has contemporarily been used as monotherapy in epileptic patients (8) & has proven efficacy over the CBZ. In trigeminal neuralgia, though various studies have shown that OXC produce lesser side effects, but none of the studies have compared the efficacy of carbamazepine with oxcarbazepine . Thus the present study intends to compare the efficacy of oxcarbazepine with carbamazepine as monotherapy in patients suffering from trigeminal neuralgia.


Recruitment information / eligibility

Status Recruiting
Enrollment 132
Est. completion date January 31, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility INCLUSION CRITERIA: - Clinically proven cases of primary trigeminal neuralgia. - Patients who are willing to participate in the study. EXCLUSION CRITERIA: - Intolerance to either of the two drugs - Medically compromised patients - Patients with pacemaker - Patients who have previously undergone surgical treatment for TRIGEMINAL NEURALGIA. - Patients who are already on pharmacotherapy for TRIGEMINAL NEURALGIA. - Seizure disorder/ pregnant/ lactating - Renal/ hepatic impairment - History of hyponatermia - Concurrent medication- dilantin, phenytoin

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oxcarbazepine
oxcarbazepine 150mg BD initial dose , followup will be done at 15days, 6weeks, 10 weeks interval
Carbamazepine
carbamazepine 100mg BD initial dose, follow up will be done 2weeks, 6 weeks & 10weeks

Locations

Country Name City State
India PGIDS Rohtak Haryana
India Post Graduate Institute of Dental Sciences Rohtak Haryana

Sponsors (1)

Lead Sponsor Collaborator
Postgraduate Institute of Dental Sciences Rohtak

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in pain scores Visual analog scale ( scale 0 to 10, where higher score means worst outcome) 10 weeks
Secondary Adverse effects of drugs in both the groups. side effects will be asked at each visit 10 weeks
Secondary Need for adding 2nd line therapy in both the groups. if pateint is not satisfied with treatment, then 2nd line drug will be used 10 weeks
Secondary Number of patients withdrawal from study due to non compliance to drug Drug tolerability in both the groups 10 weeks
Secondary Treatment satisfaction in both the groups. likert scale is used in both groups 1-5 scale, higher score means better outcome 10 weeks
Secondary Quality of life in both the groups. Oral health impact profile 14 score will be used, higher score means worst outcome 10 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05152368 - Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Trigeminal Neuralgia and Peripheral Neuropathy Phase 1
Recruiting NCT02801630 - An Evaluation of the Effect of a Surface Acoustic Wave Patch Device on the Symptons of Trigeminal Neuralgia N/A
Completed NCT02473016 - Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia Phase 2
Recruiting NCT01364259 - A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia Phase 3
Completed NCT01364272 - Diffusion Tensor Imaging Magnetic Resonance Imaging (DTI MRI) as a Correlate to Pain Relief and Facial Numbness in Patients Following Stereotactic Radiosurgical Rhizotomy for Trigeminal Neuralgia
Completed NCT00603694 - Hippocampal Radiation Exposure and Memory N/A
Completed NCT00913107 - Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia Phase 2/Phase 3
Completed NCT06240494 - Predictive Factors in Maxillary and Mandibular Nerve Radiofrequency Treatment for Trigeminal Neuralgia
Completed NCT05712993 - Comparative Study Between Transcoronoid and Infrazygomatic Anterior Maneuvers N/A
Completed NCT04371575 - Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - a Prospective Study in 60 Patients
Completed NCT03669744 - Regional Anesthesia in Refractory Trigeminal Neuralgia: 21 Cases Reported to the Limoges University Hospital
Completed NCT05032573 - Feasibility of Olive Oil for Reducing Facial Pain of Trigeminal Neuralgia N/A
Recruiting NCT05615714 - Paresthesia-free Peripheral Nerve Field Stimulation for Trigeminal Neuralgia (FreeST Trial) Phase 1/Phase 2
Recruiting NCT04054024 - Efficacy and Tolerability of Erenumab in Patients With Trigeminal Neuralgia Phase 2
Not yet recruiting NCT05451251 - Deep Brain Stimulation for Refractory Trigeminal Neuralgia With a Demyelinating Pontine Lesion N/A
Withdrawn NCT04353505 - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Phase 1
Withdrawn NCT01932255 - CSF Leak Following Microvascular Decompression: the Benefit of Routine Postoperative Lumbar Tap N/A
Completed NCT05075707 - Comparison Between Magnetic Field and Laser Therapy in Management of Trigeminal Neuralgia N/A
Completed NCT06334796 - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology Early Phase 1
Recruiting NCT03331913 - Botulinum Toxin for Trigeminal Neuralgia Phase 3